字體：小 中 大 |
|
|
|
| 2020/11/18 03:20:04瀏覽390｜回應0｜推薦4 | |
| AbbVie Inc. (ABBV, 98.86) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinsons disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).Its EPS of 2020 and 2021 is estimated at $10.48 and $12.12 respectively. It represents an increase of 98.5% and 15.64% from prior year. It also provides a divided of $5.20 per share (Yield =5.24%). IN addition, Its PE ratio is only 9.53 and way under value. Buy it at $98.78 or lower and sell it at $126 or higher. (投資有風險，請謹慎評估，若決定購買，請自設停損）
法律聲明： 我目前持有以上的股票 (美西時間：11:43 AM 11-17-20) 追蹤行動： 01. 我們昨天移動約2億美金到ABBV。（美西時間：04:27 AM 11-18-20) |
|
| ( 知識學習｜商業管理 ) |
